GlassScriptPhysician profile
Neshat Tebyanian
NPI 1396060521
$1,622.93
in general payments reported to CMS, 2019-2025
15 companies · $28.48 in 2025
The $28.48 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $362 · 2023: $670 · 2024: $312 · 2025: $28.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.76 |
| Education | $125.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $449.39 | 2021-2024 | Dupixent |
| Glaxosmithkline, LLC. | $288.67 | 2021-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $227.35 | 2022-2024 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $190.99 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $95.33 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Pfizer INC. | $50.69 | 2021-2023 | |
| Genentech USA, INC. | $47.17 | 2021-2022 | |
| Abbvie INC. | $43.77 | 2023-2024 | |
| Kaleo, INC. | $41.71 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $41.12 | 2021-2023 | Airduo Digihaler |
| Coopersurgical, INC. | $28.48 | 2025 | Paragard T 380a |
| Biocryst US Sales Co., LLC | $24.65 | 2024 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $24.65 | 2023 | Takhzyro |
| Amgen INC. | $14.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neshat Tebyanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.